Table 2 Background of second-line anti-VEGF drug trials
Trial | ML18147 Ref. [11] | RAISE Ref. [4] | VELOUR Ref. [3] | |||
|---|---|---|---|---|---|---|
Number of cases | 820 | 1072 | 1226 | |||
Prior oxaliplatin | 41.8% | 100% | 100% | |||
Prior bevacizumab | 100% | 100% | 30.5% | |||
Backbone chemotherapy | Irinotecan (35%) | FOLFIRI | FOLFIRI | |||
Design | Open label | Double blind | Double blind | |||
Combination | With BEV | Without BEV | With RAM | Without RAM | With AFL | Without AFL |
ORR | 5% | 3% | 13.4% | 12.5% | 19.8% | 11.1% |
PFS (months) | 5.7 | 4.1 | 5.7 | 4.5 | 6.90 | 4.67 |
HR 0.68 | p < .0001 | HR0.793 | p < .0005 | HR0.758 | p < .0001 | |
OS (months) | 11.2 | 9.8 | 13.3 | 11.7 | 13.50 | 12.06 |
HR 0.81 | p = .0062 | HR 0.844 | p = .0219 | HR 0.817 | p = .0032 | |